Navigation Links
Patients Of MS Are Not At Risk From The Interferon Treatment

Research suggests that the patients of multiple sclerosis (MS) may gain from treatment with Interferon and// not be at risk from it.

Although treatment with interferon appears to reduce the formation of new areas of damage in the brains of patients with multiple sclerosis (MS), including lesions that appear as highly contrasted images, called black holes, on magnetic resonance imaging (MRI), treatment does not appear to affect the duration of these damaged regions, according to a new study posted online by Archives of Neurology.

Previous studies have shown that treatment with interferon beta-1b, a chemical that has activity on the immune system, reduces the formation of lesions visible to MRI, according to background information in the article. Chronic, persisting black holes reflect areas of irreversible nerve fiber loss and permanent damage. Black holes of shorter duration are believed to reflect the presence of short-term swelling. Shortening the duration of black holes, the authors suggest, may prevent the formation of permanent detrimental lesions, ultimately exerting a neuro-protective effect.

Researchers from the National Institute of Neurological Disorders and Stroke, Bethesda, had analyzed MRIs for both the formation and duration of black holes for six patients with relapsing-remitting type MS. Monthly MRIs were obtained for 36 months before the treatment was initiated (natural history phase) and for 36 months during treatment with interferon (therapy phase).

The researchers found that the number of new black holes increased during both the treatment and natural history phases for all patients, but the accumulation of new black holes was substantially lower for patients during the treatment phase. The duration of new black holes arising during the treatment phase was not shorter than the duration of black holes arising during the natural history phase, however.

Source: Newswise

Medindia on Multiple Sclerosis

Multiple Sclerosis: Multiple sclerosis is a chronic neurological disease of the central nervous system. There is no cure for this disease but modern day treatment may slow the course of development or give relief from some of the symptoms of this disease.

'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability ... Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, ... range. With color spectrum tools users can visually see the color range effected with ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New Jersey ... as well as advocacy for the state and region‘s technology businesses, hosted their ... The Council's Innovation Forecast event highlights innovation throughout the region from small to ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care ... a top priority because it’s not if you will be attacked, but when.” However, ... it comes to digital health care. , Improvements in auditing and monitoring have taken ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and ... this year. Dyer started as the Chairman of the Management Committee when IFN ... the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the Cowen and Company ... Boston Marriott Copley Place on Tuesday, March 7, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
(Date:2/24/2017)... , Feb. 24, 2017 Medical information ... to increase their self-service capabilities to manage inquiries ... (HCPs). New research from consulting leader ... have developed self-service website portals where HCPs can ... just one of many findings to emerge from ...
Breaking Medicine Technology: